Search results
Showing results for
Theolytics, a clinical‑stage biotechnology company developing next‑generation oncolytic immunotherapies, announces that it has relocated to new, state‑of‑the‑art facilities at ARC Oxford, a growing science and innovation campus close to Oxford’s world‑class research institutes, teaching hospitals and university. The company joins a thriving community of more than 30 science and technology companies at ARC Oxford, further strengthening the campus’ position as a hub for cutting‑edge innovation.
